In this article, we consider how artificial intelligence (AI) is not merely an auxiliary tool but an essential partner in the biopharmaceutical industry’s pursuit of innovative therapies and life-changing medications. It has the potential to bring about a paradigm shift in the way that novel treatments are discovered and delivered. However, proactive measures, including establishing clear standards for data quality and collaborative efforts in regulatory frameworks, are pivotal steps toward realising the full benefits of AI in biopharmaceuticals.